October 22, 2020 – BD (Becton, Dickinson and Company) announced the appointment of Patrick Kaltenbach as EVP and chief technology officer, and the promotion of Dave Hickey to EVP and president, Life Sciences segment, both effective January 1, 2021.
Kaltenbach will be responsible for continuing to drive the company’s category innovation strategy and leading all research and development (R&D) activities, including executing the current innovation pipeline and developing the future product portfolio.
As CTO, Kaltenbach will also oversee the company’s recently launched “Innovation and Growth Fund” to advance BD’s strategy and increase investments in priority R&D programs that accelerate growth.
Kaltenbach succeeds John DeFord in the chief technology officer role. DeFord, who joined BD through the 2017 acquisition of C. R. Bard, Inc., recently announced his intention to retire at the end of the calendar year. DeFord will continue to serve as an advisor and technical and scientific consultant for BD upon his retirement.
Succeeding Kaltenbach as EVP and president of the Life Sciences segment is Dave Hickey, who currently is worldwide president of the Integrated Diagnostics Solutions business. As president of the Life Sciences segment, Hickey will oversee the Biosciences, Preanalytical Systems and Diagnostics Systems businesses worldwide.